Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2025
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With MenJoel M Palefsky, Anna R Giuliano, Stephen E Goldstone, et al.
Human Vaccines & Immunotherapeutics|October 15, 2025
Summary of final data from the 9-valent human papillomavirus vaccine pregnancy registry (2014-2021)Cathy Hardalo, Ann Marko, Brittany Sciba, et al.
The Journal of Infectious Diseases|November 28, 2023
High Risk of New HPV Infection Acquisition Among Unvaccinated Young MenAnna R Giuliano, Joel M Palefsky, Stephen E Goldstone, et al.
Vaccine|March 2, 2022
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United KingdomVincent Daniels, Kunal Saxena, Oscar Patterson-Lomba, et al.
Vaccine|August 10, 2017
Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccineAna Guevara, Robinson Cabello, Linn Woelber, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesChristine Roberts, Tina Green, Erica Hess, et al.
Vaccine|July 31, 2010
Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodiesSylvia van Drunen Littel-van den Hurk, Zoe Lawman, Don Wilson, et al.
Human Vaccines & Immunotherapeutics|September 28, 2018
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccineAna Maria Guevara, Eugenio Suarez, Alejandro Victoria, et al.
The Pediatric Infectious Disease Journal|June 20, 2015
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old GirlsTimo Vesikari, Nicholas Brodszki, Pierre van Damme, et al.
Human Vaccines & Immunotherapeutics|August 23, 2022
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participantsSuzanne M Garland, Manjula Anagani, Neerja Bhatla, et al.
Pageof 7